Overview

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Alexion Pharma GmbH
Origin Biosciences
Treatments:
Molybdenum